Table 2.

Comparison between the different studied subgroups according to the level of IFN-gamma and IL-10 in brain homogenate

	Ia (n = 10)	Ib (n = 10)	IIa1 (n = 10)	IIa2 (n = 10)	IIa3 (n = 10)	IIb (n = 10)	F	p
IFN-gamma (pg/ml)
Median (Min – Max)	1.1 (0.8–1.1)	1.9 (1.7–2.2)	1.1 (1–1.4)	1.3 (1–1.5)	1.7 (1.5–1.9)	1.9 (1.7–2.1)	62.602*	<0.001*
Mean ± SD.	1 ± 0.1	1.9 ± 0.2	1.1 ± 0.2	1.3 ± 0.2	1.7 ± 0.2	1.9 ± 0.2
p1		<0.001*	0.454	0.008*	<0.001*	<0.001*
p2			<0.001*	<0.001*	0.010*	1.000
p3			<0.001*	<0.001*	0.028*
Significance between subgroups			p4 = 0.480,p5 < 0.001*, p6 < 0.001*
IL-10 (ng/ml)
Median (Min – Max)	1.3 (1–1.5)	7.9 (7.6–8.3)	2.7 (2–3)	4 (3.5–4.3)	5.9 (5.3–6.3)	7.7 (6.9–8.5)	875.150*	<0.001*
Mean ± SD.	1.3 ± 0.2	7.9 ± 0.2	3 ± 2.6	4 ± 0.3	5.9 ± 0.4	7.7 ± 0.2
p1		<0.001*	<0.001*	<0.001*	<0.001*	<0.001*
p2			<0.001*	<0.001*	<0.001*	0.480
p3			<0.001*	<0.001*	<0.001*
Significance between subgroups			p4 < 0.001*,p5 < 0.001*, p6 < 0.001*

F: F for ANOVA test, a pairwise comparison between each two subgroups was done using Post Hoc Test (Tukey)

p: p value for comparing between the different studied subgroups

p₁: p value for comparing between Ia and Ib, IIa1, IIa2, IIa3, IIb

p₂: p value for comparing between Ib and IIa1, IIa2, IIa3, IIb

p₃: p value for comparing between IIb and IIa1, IIa2, IIa3

p₄: p value for comparing between IIa1 and IIa2

p₅: p value for comparing between IIa1 and IIa3

p₆: p value for comparing between IIa2 and IIa3

*: Statistically significant at p ≤ 0.05

Ia: Healthy control, Ib: Infected control, IIa1: Aluvia-treated (day zero), IIa2: Aluvia-treated (second week), IIa3: Aluvia-treated (eighth week), IIb: Therapeutic control